Reports Q1 revenue $11.37M, consensus $10.6M. "During the first quarter of 2023, we demonstrated progress towards achieving our goals for 2023. At one-year post-launch, IBSRELA is being recognized as an important medicine for IBS-C and is delivering meaningful benefits to patients. We are consistently gaining market share with our innovative commercial strategy. At the same time, during the first quarter, we continued to advance XPHOZAH to approval and launch and pursued business development opportunities that would bring our novel mechanism technologies to patients and strengthen our cash position," said Mike Raab, president and chief executive officer of Ardelyx. "As we look towards the remainder of the year, we will continue to focus on achieving our near-term milestones, including driving IBSRELA adoption, preparing to launch XPHOZAH in the second half of this year pending FDA approval, and building on our strategy for the next phase of the company’s growth."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARDX:
- Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
- Ardelyx options imply 10.0% move in share price post-earnings
- Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
- Ardelyx announces additional data supporting first-in-class IBSRELA
- Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023